A Bayesian multi-risks survival (MRS) model in the presence of double censorings. DE Castro, Mário, Ming-Hui Chen, Yuanye Zhang, and Anthony V. D'Amico. "A Bayesian multi-risks survival (MRS) model in the presence of double censorings." Biometrics 76, no. 4 (2020): 1297-1309. Read more about A Bayesian multi-risks survival (MRS) model in the presence of double censorings.PubMed
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp Blackwell, Kimberly, Roman Donskih, Michael C Jones, Allen Nixon, Maria J. Vidal, Roumen Nakov, Pritibha Singh, Gregor Schaffar, Pere Gascón, and Nadia Harbeck. "A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supp." Oncologist 21, no. 7 (2016): 789-94. Read more about A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (SuppPubMed
A Massive Data Framework for M-Estimators with Cubic-Rate. Shi, Chengchun, Wenbin Lu, and Rui Song. "A Massive Data Framework for M-Estimators with Cubic-Rate." J Am Stat Assoc 113, no. 524 (2018): 1698-1709. Read more about A Massive Data Framework for M-Estimators with Cubic-Rate.PubMed
A model-based conditional power assessment for decision making in randomized controlled trial studies. Zou, Baiming, Jianwen Cai, Gary G. Koch, Haibo Zhou, and Fei Zou. "A model-based conditional power assessment for decision making in randomized controlled trial studies." Stat Med 36, no. 30 (2017): 4765-4776. Read more about A model-based conditional power assessment for decision making in randomized controlled trial studies.PubMed
A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression. Xia, Fang, Stephen L. George, and Xiaofei Wang. "A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression." Stat Biopharm Res 8, no. 1 (2016): 12-21. Read more about A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.PubMed
A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring. Zhao, Yue, Amy H. Herring, Haibo Zhou, Mirza W. Ali, and Gary G. Koch. "A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring." J Biopharm Stat 24, no. 2 (2014): 229-53. Read more about A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring.PubMed
A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events. Potthoff, Richard F., and Susan Halabi. "A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events." Pharm Stat 14, no. 4 (2015): 273-83. Read more about A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.PubMed
A practical Bayesian adaptive design incorporating data from historical controls. Psioda, Matthew A., Mat Soukup, and Joseph G. Ibrahim. "A practical Bayesian adaptive design incorporating data from historical controls." Stat Med 37, no. 27 (2018): 4054-4070. Read more about A practical Bayesian adaptive design incorporating data from historical controls.PubMed
A regularized variable selection procedure in additive hazards model with stratified case-cohort design. Ni, Ai, and Jianwen Cai. "A regularized variable selection procedure in additive hazards model with stratified case-cohort design." Lifetime Data Anal 24, no. 3 (2018): 443-463. Read more about A regularized variable selection procedure in additive hazards model with stratified case-cohort design.PubMed
A varying-coefficient generalized odds rate model with time-varying exposure: An application to fitness and cardiovascular disease mortality. Zhou, Jie, Jiajia Zhang, Alexander C. Mclain, Wenbin Lu, Xuemei Sui, and James W. Hardin. "A varying-coefficient generalized odds rate model with time-varying exposure: An application to fitness and cardiovascular disease mortality." Biometrics 75, no. 3 (2019): 853-863. Read more about A varying-coefficient generalized odds rate model with time-varying exposure: An application to fitness and cardiovascular disease mortality.PubMed
Accelerated intensity frailty model for recurrent events data. Liu, Bo, Wenbin Lu, and Jiajia Zhang. "Accelerated intensity frailty model for recurrent events data." Biometrics 70, no. 3 (2014): 579-87. Read more about Accelerated intensity frailty model for recurrent events data.PubMed
Additive mixed effect model for clustered failure time data. Cai, Jianwen, and Donglin Zeng. "Additive mixed effect model for clustered failure time data." Biometrics 67, no. 4 (2011): 1340-51. Read more about Additive mixed effect model for clustered failure time data.PubMed
AEBSD: Sample size of AEBSD and Comparison with BSD (R) Wang, Ting. AEBSD: Sample size of AEBSD and Comparison with BSD (R)., 2018. Read more about AEBSD: Sample size of AEBSD and Comparison with BSD (R)
Age and African-American race impact the validity and reliability of the asthma control test in persistent asthmatics. Burbank, Allison J., Krista Todoric, Pamela Steele, Jonathan Rosen, Haibo Zhou, Marcia Frye, Ceila E. Loughlin, Sally Ivins, Katherine Mills, Lauren Dembnicki Massey et al. "Age and African-American race impact the validity and reliability of the asthma control test in persistent asthmatics." Respir Res 19, no. 1 (2018): 152. Read more about Age and African-American race impact the validity and reliability of the asthma control test in persistent asthmatics.PubMed
An Expectation Maximization algorithm for fitting the generalized odds-rate model to interval censored data. Zhou, Jie, Jiajia Zhang, and Wenbin Lu. "An Expectation Maximization algorithm for fitting the generalized odds-rate model to interval censored data." Stat Med 36, no. 7 (2017): 1157-1171. Read more about An Expectation Maximization algorithm for fitting the generalized odds-rate model to interval censored data.PubMed
Analysis of multiple survival events in generalized case-cohort designs. Kim, Soyoung, Donglin Zeng, and Jianwen Cai. "Analysis of multiple survival events in generalized case-cohort designs." Biometrics 74, no. 4 (2018): 1250-1260. Read more about Analysis of multiple survival events in generalized case-cohort designs.PubMed
Analysis of secondary phenotypes in multigroup association studies. Zhou, Fan, Haibo Zhou, Tengfei Li, and Hongtu Zhu. "Analysis of secondary phenotypes in multigroup association studies." Biometrics 76, no. 2 (2020): 606-618. Read more about Analysis of secondary phenotypes in multigroup association studies.PubMed
Analysis of the Proportional Hazards Model with Sparse Longitudinal Covariates. Cao, Hongyuan, Mathew M. Churpek, Donglin Zeng, and Jason P. Fine. "Analysis of the Proportional Hazards Model with Sparse Longitudinal Covariates." J Am Stat Assoc 110, no. 511 (2015): 1187-1196. Read more about Analysis of the Proportional Hazards Model with Sparse Longitudinal Covariates.PubMed
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Roe, Matthew T., Derek D. Cyr, Debra Eckart, Phillip J. Schulte, Michael A. Morse, Kimberly L. Blackwell, Neal E. Ready, Yousuf S Zafar, Anne W. Beaven, John H. Strickler et al. "Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." Eur Heart J 37, no. 4 (2016): 412-22. Read more about Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.PubMed
Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development. Ma, Guoguang Julie, Eric Chi, Joseph G. Ibrahim, and Robert A. Parker. "Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development." Stat Biopharm Res 4, no. 3 (2012): 293-300. Read more about Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development.PubMed
Assessing temporal agreement between central and local progression-free survival times. Zeng, Donglin, Emil Cornea, Jun Dong, Jean Pan, and Joseph G. Ibrahim. "Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58. Read more about Assessing temporal agreement between central and local progression-free survival times.PubMed
AsynchLong: Regression analysis of sparse asynchronous longitudinal data (R). Cao, Hongyuan, Donglin Zeng, Jason P. Fine, and Shannon T. Holloway. AsynchLong: Regression analysis of sparse asynchronous longitudinal data (R).. 2.0 ed., 2016. Read more about AsynchLong: Regression analysis of sparse asynchronous longitudinal data (R).
Auxiliary variable-enriched biomarker-stratified design. Wang, Ting, Xiaofei Wang, Haibo Zhou, Jianwen Cai, and Stephen L. George. "Auxiliary variable-enriched biomarker-stratified design." Stat Med 37, no. 30 (2018): 4610-4635. Read more about Auxiliary variable-enriched biomarker-stratified design.PubMed
Bayesian clinical trial design using historical data that inform the treatment effect. Psioda, Matthew A., and Joseph G. Ibrahim. "Bayesian clinical trial design using historical data that inform the treatment effect." Biostatistics 20, no. 3 (2019): 400-415. Read more about Bayesian clinical trial design using historical data that inform the treatment effect.PubMed
Bayesian design of a survival trial with a cured fraction using historical data. Psioda, Matthew A., and Joseph G. Ibrahim. "Bayesian design of a survival trial with a cured fraction using historical data." Stat Med 37, no. 26 (2018): 3814-3831. Read more about Bayesian design of a survival trial with a cured fraction using historical data.PubMed
Bayesian design of biosimilars clinical programs involving multiple therapeutic indications. Psioda, Matthew A., Kuolung Hu, Yang Zhang, Jean Pan, and Joseph G. Ibrahim. "Bayesian design of biosimilars clinical programs involving multiple therapeutic indications." Biometrics 76, no. 2 (2020): 630-642. Read more about Bayesian design of biosimilars clinical programs involving multiple therapeutic indications.PubMed
Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching. Zhang, Yuanye, Ming-Hui Chen, Joseph G. Ibrahim, Donglin Zeng, Qingxia Chen, Zhiying Pan, and Xiaodong Xue. "Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching." Lifetime Data Anal 20, no. 1 (2014): 76-105. Read more about Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching.PubMed
BAYESIAN INFERENCE OF HIDDEN GAMMA WEAR PROCESS MODEL FOR SURVIVAL DATA WITH TIES. Sinha, Arijit, Zhiyi Chi, and Ming-Hui Chen. "BAYESIAN INFERENCE OF HIDDEN GAMMA WEAR PROCESS MODEL FOR SURVIVAL DATA WITH TIES." Stat Sin 25, no. 4 (2015): 1613-1635. Read more about BAYESIAN INFERENCE OF HIDDEN GAMMA WEAR PROCESS MODEL FOR SURVIVAL DATA WITH TIES.PubMed
Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690. Ibrahim, Joseph G., Ming-Hui Chen, and Haitao Chu. "Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690." BMC Med Res Methodol 12 (2012): 183. Read more about Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690.PubMed
Biomarker threshold adaptive designs for survival endpoints. Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054. Read more about Biomarker threshold adaptive designs for survival endpoints.PubMed
BTAD : Biomarker Threshold Adaptive Designs for Survival Endpoints (C++) Diao, Guoqing, Jun Dong, Donglin Zeng, and Joseph G. Ibrahim. BTAD : Biomarker Threshold Adaptive Designs for Survival Endpoints (C++)., 2018. Read more about BTAD : Biomarker Threshold Adaptive Designs for Survival Endpoints (C++)
Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. George, Stephen L., Xiaofei Wang, and Herbert Pang. Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis.. Boca Raton: Chapman & Hall / CRC Press, 2016. Read more about Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis.
Case-cohort studies with interval-censored failure time data. Zhou, Q, H Zhou, and J Cai. "Case-cohort studies with interval-censored failure time data." Biometrika 104, no. 1 (2017): 17-29. Read more about Case-cohort studies with interval-censored failure time data.PubMed
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. Hamy, Anne-Sophie, Sandrine Tury, Xiaofei Wang, Junheng Gao, Jean-Yves Pierga, Sylvie Giacchetti, Etienne Brain, Barbara Pistilli, Michel Marty, Marc Espié et al. "Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial." J Clin Oncol 37, no. 8 (2019): 624-635. Read more about Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.PubMed
Censored Rank Independence Screening for High-dimensional Survival Data. Song, Rui, Wenbin Lu, Shuangge Ma, and Jessie X Jeng. "Censored Rank Independence Screening for High-dimensional Survival Data." Biometrika 101, no. 4 (2014): 799-814. Read more about Censored Rank Independence Screening for High-dimensional Survival Data.PubMed
Change-Plane Analysis for Subgroup Detection and Sample Size Calculation. Fan, Ailin, Rui Song, and Wenbin Lu. "Change-Plane Analysis for Subgroup Detection and Sample Size Calculation." J Am Stat Assoc 112, no. 518 (2017): 769-778. Read more about Change-Plane Analysis for Subgroup Detection and Sample Size Calculation.PubMed
Clinical trials data collection: when less is more. Sargent, Daniel J., and Stephen L. George. "Clinical trials data collection: when less is more." J Clin Oncol 28, no. 34 (2010): 5019-21. Read more about Clinical trials data collection: when less is more.PubMed
Comment. Ivanova, A, K M. Anderson, Gary L. Rosner, and E Rubin. "Comment." Stat Biopharm Res 7, no. 4 (2015): 357-358. Read more about Comment.PubMed
Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result? Parke, Tom, Olga Marchenko, Vladimir Anisimov, Anastasia Ivanova, Christopher Jennison, Inna Perevozskaya, and Guochen Song. "Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?" J Biopharm Stat 27, no. 3 (2017): 457-476. Read more about Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?PubMed
Comparison of operational characteristics for binary tests with clustered data. Kwak, Minjung, Sang-Won Um, and Sin-Ho Jung. "Comparison of operational characteristics for binary tests with clustered data." Stat Med 34, no. 15 (2015): 2325-33. Read more about Comparison of operational characteristics for binary tests with clustered data.PubMed
Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. He, Kevin, Yanming Li, Ji Zhu, Hongliang Liu, Jeffrey E. Lee, Christopher I. Amos, Terry Hyslop, Jiashun Jin, Huazhen Lin, Qinyi Wei et al. "Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates." Bioinformatics 32, no. 1 (2016): 50-7. Read more about Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates.PubMed
Computationally Efficient Estimation for the Generalized Odds Rate Mixture Cure Model with Interval-Censored Data. Zhou, Jie, Jiajia Zhang, and Wenbin Lu. "Computationally Efficient Estimation for the Generalized Odds Rate Mixture Cure Model with Interval-Censored Data." J Comput Graph Stat 27, no. 1 (2018): 48-58. Read more about Computationally Efficient Estimation for the Generalized Odds Rate Mixture Cure Model with Interval-Censored Data.PubMed
CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method. Bayar, Mohamed Amine, Anastasia Ivanova, and Gwenael Le Teuff. "CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed 176 (2019): 211-223. Read more about CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.PubMed
CRM2DIM: Dual-Agent Bayesian Continual Reassessment Method (SAS) Bayar, Mohamed, Anastasia Ivanova, and Gwenael Le Teuff. CRM2DIM: Dual-Agent Bayesian Continual Reassessment Method (SAS). 1.0 ed., 2019. Read more about CRM2DIM: Dual-Agent Bayesian Continual Reassessment Method (SAS)
Data fraud in clinical trials. George, Stephen L., and Marc Buyse. "Data fraud in clinical trials." Clin Investig (Lond) 5, no. 2 (2015): 161-173. Read more about Data fraud in clinical trials.PubMed
Design of Phase II Non-inferiority Trials. Jung, Sin-Ho. "Design of Phase II Non-inferiority Trials." Contemp Clin Trials Commun 7 (2017): 23-27. Read more about Design of Phase II Non-inferiority Trials.PubMed
Design of phase III clinical trials George, Stephen L.. "Design of phase III clinical trials." In Oncology Clinical Trials: Successful Design, Conduct, and Analysis. New York: Demos Medical Publishing, LLC, 2010.Oncology Clinical Trials: 11. Design of phase III clinical trials Read more about Design of phase III clinical trials
Determining the Number of Latent Factors in Statistical Multi-Relational Learning. Shi, Chengchun, Wenbin Lu, and Rui Song. "Determining the Number of Latent Factors in Statistical Multi-Relational Learning." J Mach Learn Res 20 (2019). Read more about Determining the Number of Latent Factors in Statistical Multi-Relational Learning.PubMed
Dose-finding designs for trials of molecularly targeted agents and immunotherapies. Chiuzan, Cody, Jonathan Shtaynberger, Gulam A. Manji, Jimmy K. Duong, Gary K. Schwartz, Anastasia Ivanova, and Shing M. Lee. "Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494. Read more about Dose-finding designs for trials of molecularly targeted agents and immunotherapies.PubMed
DOUBLY ROBUST ESTIMATION OF OPTIMAL TREATMENT REGIMES FOR SURVIVAL DATA-WITH APPLICATION TO AN HIV/AIDS STUDY. Jiang, Runchao, Wenbin Lu, Rui Song, Michael G. Hudgens, and Sonia Naprvavnik. "DOUBLY ROBUST ESTIMATION OF OPTIMAL TREATMENT REGIMES FOR SURVIVAL DATA-WITH APPLICATION TO AN HIV/AIDS STUDY." Ann Appl Stat 11, no. 3 (2017): 1763-1786. Read more about DOUBLY ROBUST ESTIMATION OF OPTIMAL TREATMENT REGIMES FOR SURVIVAL DATA-WITH APPLICATION TO AN HIV/AIDS STUDY.PubMed
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. Stinchcombe, Thomas E., Pasi A. Jänne, Xiaofei Wang, Erin M. Bertino, Jared Weiss, Lyudmila Bazhenova, Lin Gu, Christie Lau, Cloud Paweletz, Anthony Jaslowski et al. "Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial." JAMA Oncol 5, no. 10 (2019): 1448-1455. Read more about Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.PubMed
Efficient estimation for accelerated failure time model under case-cohort and nested case-control sampling. Kang, Suhyun, Wenbin Lu, and Mengling Liu. "Efficient estimation for accelerated failure time model under case-cohort and nested case-control sampling." Biometrics 73, no. 1 (2017): 114-123. Read more about Efficient estimation for accelerated failure time model under case-cohort and nested case-control sampling.PubMed
Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data. Diao, Guoqing, Donglin Zeng, and Song Yang. "Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9. Read more about Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data.PubMed
Embracing rejection: Immunologic trends in brain metastasis. S Farber, Harrison, Vadim Tsvankin, Jessica L. Narloch, Grace J. Kim, April K. S. Salama, Gordana Vlahovic, Kimberly L. Blackwell, John P. Kirkpatrick, and Peter E. Fecci. "Embracing rejection: Immunologic trends in brain metastasis." Oncoimmunology 5, no. 7 (2016): e1172153. Read more about Embracing rejection: Immunologic trends in brain metastasis.PubMed
Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses. Zhang, Jianrong, Wenhua Liang, Hengrui Liang, Xiaofei Wang, and Jianxing He. "Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses." Ann Transl Med 7, no. 11 (2019): 244. Read more about Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses.PubMed
Endpoints for cancer clinical trials. George, Stephen L., Xiaofei Wang, and Herbert Pang. "Endpoints for cancer clinical trials." In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. Boca Raton: Chapman & Hall / CRC Press, 2016. Read more about Endpoints for cancer clinical trials.
Enriched biomarker-driven clinical trials. Wang, Xiaofei, Jianwen Cai, and Stephen L. George. Enriched biomarker-driven clinical trials. In Wiley StatsRef: Statistics Reference Online. Wiley, 2019. Read more about Enriched biomarker-driven clinical trials.
Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials. Song, Guochen, and Anastasia Ivanova. "Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials." J Biopharm Stat 25, no. 6 (2015): 1206-14. Read more about Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials.PubMed
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. Pang, Herbert H., Xiaofei Wang, Thomas E. Stinchcombe, Melisa L. Wong, Perry Cheng, Apar Kishor Ganti, Daniel J. Sargent, Ying Zhang, Chen Hu, Sumithra J. Mandrekar et al. "Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012." J Clin Oncol 34, no. 33 (2016): 3992-3999. Read more about Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.PubMed
Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme. Ding, Jieli, Haibo Zhou, Yanyan Liu, Jianwen Cai, and Matthew P. Longnecker. "Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme." Biostatistics 15, no. 4 (2014): 636-50. Read more about Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme.PubMed
Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker. Joshi, Neha, Jason Fine, Rong Chu, and Anastasia Ivanova. "Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker." J Biopharm Stat 29, no. 4 (2019): 685-695. Read more about Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker.PubMed
Estimating time-varying effects for overdispersed recurrent events data with treatment switching. Chen, Qingxia, Donglin Zeng, Joseph G. Ibrahim, Mouna Akacha, and Heinz Schmidli. "Estimating time-varying effects for overdispersed recurrent events data with treatment switching." Biometrika 100, no. 2 (2013): 339-354. Read more about Estimating time-varying effects for overdispersed recurrent events data with treatment switching.PubMed
Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study. Zeng, Donglin, Qingxia Chen, Ming-Hui Chen, and Joseph G. Ibrahim. "Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study." Biometrika 99, no. 1 (2012): 167-184. Read more about Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study.PubMed
Estimation After a Group Sequential Trial. Milanzi, Elasma, Geert Molenberghs, Ariel Alonso, Michael G. Kenward, Anastasios A. Tsiatis, Marie Davidian, and Geert Verbeke. "Estimation After a Group Sequential Trial." Stat Biosci 7, no. 2 (2015): 187-205. Read more about Estimation After a Group Sequential Trial.PubMed
Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcome. Tan, Ziwen, Guoyou Qin, and Haibo Zhou. "Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcome." Biostatistics 17, no. 4 (2016): 663-76. Read more about Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcome.PubMed
Estimation of AUC or Partial AUC under Test-Result-Dependent Sampling. Wang, Xiaofei, Junling Ma, Stephen George, and Haibo Zhou. "Estimation of AUC or Partial AUC under Test-Result-Dependent Sampling." Stat Biopharm Res 4, no. 4 (2012): 313-323. Read more about Estimation of AUC or Partial AUC under Test-Result-Dependent Sampling.PubMed
Failure time regression with continuous informative auxiliary covariates. Ghosh, Lipika, Jiancheng Jiang, Yanqing Sun, and Haibo Zhou. "Failure time regression with continuous informative auxiliary covariates." J Stat Distrib Appl 2 (2015): 2. Read more about Failure time regression with continuous informative auxiliary covariates.PubMed
Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. Chen, Liddy M., Joseph G. Ibrahim, and Haitao Chu. "Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses." J Biopharm Stat 24, no. 4 (2014): 817-33. Read more about Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.PubMed
FSEM: Functional Structural Equation Models for Twin Functional Data. Luo, S, R Song, M Styner, J H. Gilmore, and H Zhu. "FSEM: Functional Structural Equation Models for Twin Functional Data." J Am Stat Assoc 114, no. 525 (2019): 344-357. Read more about FSEM: Functional Structural Equation Models for Twin Functional Data.PubMed
Gene selection using iterative feature elimination random forests for survival outcomes. Pang, Herbert, Stephen L. George, Ken Hui, and Tiejun Tong. "Gene selection using iterative feature elimination random forests for survival outcomes." IEEE/ACM Trans Comput Biol Bioinform 9, no. 5 (2012): 1422-31. Read more about Gene selection using iterative feature elimination random forests for survival outcomes.PubMed
geneSelRSF: Gene selection using iterative recursive feature elimination (R). Pang, Herbert. geneSelRSF: Gene selection using iterative recursive feature elimination (R).. 1.0 ed., 2012. Read more about geneSelRSF: Gene selection using iterative recursive feature elimination (R).
GHREG: Semiparametric general hazards rate model for right-censored data (C). Diao, Guoqing. GHREG: Semiparametric general hazards rate model for right-censored data (C).., 2013. Read more about GHREG: Semiparametric general hazards rate model for right-censored data (C).
GORCure: Fit Generalized Odds Rate Mixture Cure Model with Interval Censored Data (R) Zhou, Jie, Jiajia Zhang, and Wenbin Lu. GORCure: Fit Generalized Odds Rate Mixture Cure Model with Interval Censored Data (R)., 2017. Read more about GORCure: Fit Generalized Odds Rate Mixture Cure Model with Interval Censored Data (R)
High-Dimensional Inference for Personalized Treatment Decision. X Jeng, Jessie, Wenbin Lu, and Huimin Peng. "High-Dimensional Inference for Personalized Treatment Decision." Electron J Stat 12, no. 1 (2018): 2074-2089. Read more about High-Dimensional Inference for Personalized Treatment Decision.PubMed
Hypothesis testing for two-stage designs with over or under enrollment. Zeng, Donglin, Fei Gao, Kuolung Hu, Catherine Jia, and Joseph G. Ibrahim. "Hypothesis testing for two-stage designs with over or under enrollment." Stat Med 34, no. 16 (2015): 2417-26. Read more about Hypothesis testing for two-stage designs with over or under enrollment.PubMed
ICGOR: Fit Generalized Odds Rate Hazards Model with Interval Censored Data (R) Zhou, Jie, Jiajia Zhang, and Wenbin Lu. ICGOR: Fit Generalized Odds Rate Hazards Model with Interval Censored Data (R). 2.0 ed., 2017. Read more about ICGOR: Fit Generalized Odds Rate Hazards Model with Interval Censored Data (R)
ICODS: Data Analysis for ODS and Case-Cohort Designs with Interval-Censoring (R) Holloway, Shannon T., Qingning Zhou, Jianwen Cai, and Haibo Zhou. ICODS: Data Analysis for ODS and Case-Cohort Designs with Interval-Censoring (R). 1.0 ed., 2019. Read more about ICODS: Data Analysis for ODS and Case-Cohort Designs with Interval-Censoring (R)
Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy. Gao, Hao, Chris R. Kelsey, John Boyle, Tianyi Xie, Suzanne Catalano, Xiaofei Wang, and Fang-Fang Yin. "Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy." Technol Cancer Res Treat 18 (2019): 1533033819849073. Read more about Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy.PubMed
Improving efficiency of parameter estimation in case-cohort studies with multivariate failure time data. Yan, Ying, Haibo Zhou, and Jianwen Cai. "Improving efficiency of parameter estimation in case-cohort studies with multivariate failure time data." Biometrics 73, no. 3 (2017): 1042-1052. Read more about Improving efficiency of parameter estimation in case-cohort studies with multivariate failure time data.PubMed
Improving the efficiency of estimation in the additive hazards model for stratified case-cohort design with multiple diseases. Kim, Soyoung, Jianwen Cai, and David Couper. "Improving the efficiency of estimation in the additive hazards model for stratified case-cohort design with multiple diseases." Stat Med 35, no. 2 (2016): 282-93. Read more about Improving the efficiency of estimation in the additive hazards model for stratified case-cohort design with multiple diseases.PubMed
Increase in speech recognition due to linguistic mismatch between target and masker speech: monolingual and simultaneous bilingual performance. Calandruccio, Lauren, and Haibo Zhou. "Increase in speech recognition due to linguistic mismatch between target and masker speech: monolingual and simultaneous bilingual performance." J Speech Lang Hear Res 57, no. 3 (2014): 1089-97. Read more about Increase in speech recognition due to linguistic mismatch between target and masker speech: monolingual and simultaneous bilingual performance.PubMed
Interaction Screening for Ultra-High Dimensional Data. Hao, Ning, and Hao Helen Zhang. "Interaction Screening for Ultra-High Dimensional Data." J Am Stat Assoc 109, no. 507 (2014): 1285-1301. Read more about Interaction Screening for Ultra-High Dimensional Data.PubMed
JMDesign: Statistical design for joint models of longitudinal and survival data (R). Cornea, Emil, Liddy M. Chen, Bahjat Qaqish, Haitao Chu, and Joseph G. Ibrahim. JMDesign: Statistical design for joint models of longitudinal and survival data (R).. v1.1 ed., 2012. Read more about JMDesign: Statistical design for joint models of longitudinal and survival data (R).
Joint Analysis of Survival Time and Longitudinal Categorical Outcomes. Choi, Jaeun, Jianwen Cai, Donglin Zeng, and Andrew F. Olshan. "Joint Analysis of Survival Time and Longitudinal Categorical Outcomes." Stat Biosci 7, no. 1 (2015): 19-47. Read more about Joint Analysis of Survival Time and Longitudinal Categorical Outcomes.PubMed
Joint Modeling of Longitudinal and Cure-survival Data. Kim, Sehee, Donglin Zeng, Yi Li, and Donna Spiegelman. "Joint Modeling of Longitudinal and Cure-survival Data." J Stat Theory Pract 7, no. 2 (2013): 324-344. Read more about Joint Modeling of Longitudinal and Cure-survival Data.PubMed
Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates. Chen, Qingxia, Ryan C. May, Joseph G. Ibrahim, Haitao Chu, and Stephen R. Cole. "Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates." Stat Med 33, no. 26 (2014): 4560-76. Read more about Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates.PubMed
Joint modeling of survival time and longitudinal outcomes with flexible random effects. Choi, Jaeun, Donglin Zeng, Andrew F. Olshan, and Jianwen Cai. "Joint modeling of survival time and longitudinal outcomes with flexible random effects." Lifetime Data Anal 24, no. 1 (2018): 126-152. Read more about Joint modeling of survival time and longitudinal outcomes with flexible random effects.PubMed
Joint Models of Longitudinal Data and Recurrent Events with Informative Terminal Event. Kim, Sehee, Donglin Zeng, Lloyd Chambless, and Yi Li. "Joint Models of Longitudinal Data and Recurrent Events with Informative Terminal Event." Stat Biosci 4, no. 2 (2012): 262-281. Read more about Joint Models of Longitudinal Data and Recurrent Events with Informative Terminal Event.PubMed
JOINT STRUCTURE SELECTION AND ESTIMATION IN THE TIME-VARYING COEFFICIENT COX MODEL. Xiao, Wei, Wenbin Lu, and Hao Helen Zhang. "JOINT STRUCTURE SELECTION AND ESTIMATION IN THE TIME-VARYING COEFFICIENT COX MODEL." Stat Sin 26, no. 2 (2016): 547-567. Read more about JOINT STRUCTURE SELECTION AND ESTIMATION IN THE TIME-VARYING COEFFICIENT COX MODEL.PubMed
K-Sample comparisons using propensity analysis. Jung, Sin-Ho, Sang Ah Chi, and Hyun Joo Ahn. "K-Sample comparisons using propensity analysis." Biom J 61, no. 3 (2019): 698-713. Read more about K-Sample comparisons using propensity analysis.PubMed
Kappa statistic for clustered dichotomous responses from physicians and patients. Kang, Chaeryon, Bahjat Qaqish, Jane Monaco, Stacey L. Sheridan, and Jianwen Cai. "Kappa statistic for clustered dichotomous responses from physicians and patients." Stat Med 32, no. 21 (2013): 3700-19. Read more about Kappa statistic for clustered dichotomous responses from physicians and patients.PubMed
Latent class model characterization of neighborhood socioeconomic status. Palumbo, Aimee, Yvonne Michael, and Terry Hyslop. "Latent class model characterization of neighborhood socioeconomic status." Cancer Causes Control 27, no. 3 (2016): 445-52. Read more about Latent class model characterization of neighborhood socioeconomic status.PubMed
LINEAR HYPOTHESIS TESTING FOR HIGH DIMENSIONAL GENERALIZED LINEAR MODELS. Shi, Chengchun, Rui Song, Zhao Chen, and Runze Li. "LINEAR HYPOTHESIS TESTING FOR HIGH DIMENSIONAL GENERALIZED LINEAR MODELS." Ann Stat 47, no. 5 (2019): 2671-2703. Read more about LINEAR HYPOTHESIS TESTING FOR HIGH DIMENSIONAL GENERALIZED LINEAR MODELS.PubMed
Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study. Kang, Sangwook, Jianwen Cai, and Lloyd Chambless. "Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study." Biostatistics 14, no. 1 (2013): 28-41. Read more about Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study.PubMed
Marginal hazard regression for correlated failure time data with auxiliary covariates. Liu, Yanyan, Zhongshang Yuan, Jianwen Cai, and Haibo Zhou. "Marginal hazard regression for correlated failure time data with auxiliary covariates." Lifetime Data Anal 18, no. 1 (2012): 116-38. Read more about Marginal hazard regression for correlated failure time data with auxiliary covariates.PubMed
Marginal Structural Cox Models with Case-Cohort Sampling. Lee, Hana, Michael G. Hudgens, Jianwen Cai, and Stephen R. Cole. "Marginal Structural Cox Models with Case-Cohort Sampling." Stat Sin 26, no. 2 (2016): 509-526. Read more about Marginal Structural Cox Models with Case-Cohort Sampling.PubMed
mmeta: An R Package for Multivariate Meta-Analysis. Luo, Sheng, Yong Chen, Xiao Su, and Haitao Chu. "mmeta: An R Package for Multivariate Meta-Analysis." J Stat Softw 56, no. 11 (2014): 11. Read more about mmeta: An R Package for Multivariate Meta-Analysis.PubMed
mmeta: Multivariate meta-analysis (R). Luo, Sheng, Yong Chen, Xiao Su, and Haitao Chu. mmeta: Multivariate meta-analysis (R).. 2.2 ed., 2014. Read more about mmeta: Multivariate meta-analysis (R).
Modelling and estimation for optimal treatment decision with interference. Su, Lin, Wenbin Lu, and Rui Song. "Modelling and estimation for optimal treatment decision with interference." Stat (Int Stat Inst) 8, no. 1 (2019). Read more about Modelling and estimation for optimal treatment decision with interference.PubMed
Modelling recurrent events: a tutorial for analysis in epidemiology. Amorim, Leila D. A. F., and Jianwen Cai. "Modelling recurrent events: a tutorial for analysis in epidemiology." Int J Epidemiol 44, no. 1 (2015): 324-33. Read more about Modelling recurrent events: a tutorial for analysis in epidemiology.PubMed
MOMENT-BASED METHOD FOR RANDOM EFFECTS SELECTION IN LINEAR MIXED MODELS. Ahn, Mihye, Hao Helen Zhang, and Wenbin Lu. "MOMENT-BASED METHOD FOR RANDOM EFFECTS SELECTION IN LINEAR MIXED MODELS." Stat Sin 22, no. 4 (2012): 1539-1562. Read more about MOMENT-BASED METHOD FOR RANDOM EFFECTS SELECTION IN LINEAR MIXED MODELS.PubMed
More efficient estimators for case-cohort studies. Kim, S, J Cai, and W Lu. "More efficient estimators for case-cohort studies." Biometrika 100, no. 3 (2013): 695-708. Read more about More efficient estimators for case-cohort studies.PubMed
Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. Michiels, Stefan, Richard F. Potthoff, and Stephen L. George. "Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint." Stat Med 30, no. 13 (2011): 1502-18. Read more about Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.PubMed
Multiplicative rates model for recurrent events in case-cohort studies. Maitra, Poulami, Leila D. A. F. Amorim, and Jianwen Cai. "Multiplicative rates model for recurrent events in case-cohort studies." Lifetime Data Anal 26, no. 1 (2020): 134-157. Read more about Multiplicative rates model for recurrent events in case-cohort studies.PubMed
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Foster, Nathan R., Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, Penelope A. Bradbury, Suresh S. Ramalingam, David R. Gandara et al. "Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106. Read more about Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.PubMed
Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome. Zeng, Donglin, Joseph G. Ibrahim, Ming-Hui Chen, Kuolung Hu, and Catherine Jia. "Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome." J Biopharm Stat 24, no. 2 (2014): 429-42. Read more about Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome.PubMed
Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. Ivanova, Anastasia, Barry Paul, Olga Marchenko, Guochen Song, Neerali Patel, and Stergios J. Moschos. "Nine-year change in statistical design, profile, and success rates of Phase II oncology trials." J Biopharm Stat 26, no. 1 (2016): 141-9. Read more about Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.PubMed
Nonparametric estimation of the mean function for recurrent event data with missing event category. Lin, Feng-Chang, Jianwen Cai, Jason P. Fine, and Huichuan J. Lai. "Nonparametric estimation of the mean function for recurrent event data with missing event category." Biometrika 100, no. 3 (2013). Read more about Nonparametric estimation of the mean function for recurrent event data with missing event category.PubMed
odsroc: Nonparametric estimation of AUC and partial AUC under test-result-dependent sampling (R). Wang, Xiaofei, Junling Ma, Stephen L. George, and Haibo Zhou. odsroc: Nonparametric estimation of AUC and partial AUC under test-result-dependent sampling (R).., 2012. Read more about odsroc: Nonparametric estimation of AUC and partial AUC under test-result-dependent sampling (R).
On Enrichment Strategies for Biomarker Stratified Clinical Trials. Wang, Xiaofei, Jingzhu Zhou, Ting Wang, and Stephen L. George. "On Enrichment Strategies for Biomarker Stratified Clinical Trials." J Biopharm Stat 28, no. 2 (2018): 292-308. Read more about On Enrichment Strategies for Biomarker Stratified Clinical Trials.PubMed
ON ESTIMATION OF THE OPTIMAL TREATMENT REGIME WITH THE ADDITIVE HAZARDS MODEL. Kang, Suhyun, Wenbin Lu, and Jiajia Zhang. "ON ESTIMATION OF THE OPTIMAL TREATMENT REGIME WITH THE ADDITIVE HAZARDS MODEL." Stat Sin 28, no. 3 (2018): 1539-1560. Read more about ON ESTIMATION OF THE OPTIMAL TREATMENT REGIME WITH THE ADDITIVE HAZARDS MODEL.PubMed
On model selections for repeated measurement data in clinical studies. Zou, Baiming, Bo Jin, Gary G. Koch, Haibo Zhou, Stephen E. Borst, Sandeep Menon, and Jonathan J. Shuster. "On model selections for repeated measurement data in clinical studies." Stat Med 34, no. 10 (2015): 1621-33. Read more about On model selections for repeated measurement data in clinical studies.PubMed
On sample size calculation for comparing survival curves under general hypothesis testing. Jung, Sin-Ho, and Shein-Chung Chow. "On sample size calculation for comparing survival curves under general hypothesis testing." J Biopharm Stat 22, no. 3 (2012): 485-95. Read more about On sample size calculation for comparing survival curves under general hypothesis testing.PubMed
ON TESTING CONDITIONAL QUALITATIVE TREATMENT EFFECTS. Shi, Chengchun, Rui Song, and Wenbin Lu. "ON TESTING CONDITIONAL QUALITATIVE TREATMENT EFFECTS." Ann Stat 47, no. 4 (2019): 2348-2377. Read more about ON TESTING CONDITIONAL QUALITATIVE TREATMENT EFFECTS.PubMed
On variance estimate for covariate adjustment by propensity score analysis. Zou, Baiming, Fei Zou, Jonathan J. Shuster, Patrick J. Tighe, Gary G. Koch, and Haibo Zhou. "On variance estimate for covariate adjustment by propensity score analysis." Stat Med 35, no. 20 (2016): 3537-48. Read more about On variance estimate for covariate adjustment by propensity score analysis.PubMed
Optimal estimation for regression models on τ-year survival probability. Kwak, Minjung, Jinseog Kim, and Sin-Ho Jung. "Optimal estimation for regression models on τ-year survival probability." J Biopharm Stat 25, no. 3 (2015): 539-47. Read more about Optimal estimation for regression models on τ-year survival probability.PubMed
Optimal two-stage log-rank test for randomized phase II clinical trials. Kwak, Minjung, and Sin-Ho Jung. "Optimal two-stage log-rank test for randomized phase II clinical trials." J Biopharm Stat 27, no. 4 (2017): 639-658. Read more about Optimal two-stage log-rank test for randomized phase II clinical trials.PubMed
Outcome-Dependent Sampling Design and Inference for Cox's Proportional Hazards Model. Yu, Jichang, Yanyan Liu, Jianwen Cai, Dale P. Sandler, and Haibo Zhou. "Outcome-Dependent Sampling Design and Inference for Cox's Proportional Hazards Model." J Stat Plan Inference 178 (2016): 24-36. Read more about Outcome-Dependent Sampling Design and Inference for Cox's Proportional Hazards Model.PubMed
Outcome-dependent sampling with interval-censored failure time data. Zhou, Qingning, Jianwen Cai, and Haibo Zhou. "Outcome-dependent sampling with interval-censored failure time data." Biometrics 74, no. 1 (2018): 58-67. Read more about Outcome-dependent sampling with interval-censored failure time data.PubMed
Parameter estimation in Cox models with missing failure indicators and the OPPERA study. Brownstein, Naomi C., Jianwen Cai, Gary D. Slade, and Eric Bair. "Parameter estimation in Cox models with missing failure indicators and the OPPERA study." Stat Med 34, no. 30 (2015): 3984-96. Read more about Parameter estimation in Cox models with missing failure indicators and the OPPERA study.PubMed
Partial likelihood estimation of isotonic proportional hazards models. Chung, Yunro, Anastasia Ivanova, Michael G. Hudgens, and Jason P. Fine. "Partial likelihood estimation of isotonic proportional hazards models." Biometrika 105, no. 1 (2018): 133-148. Read more about Partial likelihood estimation of isotonic proportional hazards models.PubMed
Pattern mixture models for clinical validation of biomarkers in the presence of missing data. Gao, Fei, Jun Dong, Donglin Zeng, Alan Rong, and Joseph G. Ibrahim. "Pattern mixture models for clinical validation of biomarkers in the presence of missing data." Stat Med 36, no. 19 (2017): 2994-3004. Read more about Pattern mixture models for clinical validation of biomarkers in the presence of missing data.PubMed
Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression. Chen, Huaihou, Donglin Zeng, and Yuanjia Wang. "Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression." Biometrics 73, no. 4 (2017): 1343-1354. Read more about Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression.PubMed
Phase II cancer clinical trials for biomarker-guided treatments. Jung, Sin-Ho. "Phase II cancer clinical trials for biomarker-guided treatments." J Biopharm Stat 28, no. 2 (2018): 256-263. Read more about Phase II cancer clinical trials for biomarker-guided treatments.PubMed
Phase II cancer clinical trials with heterogeneous patient populations. Jung, Sin-Ho, Myron N. Chang, and Sun J. Kang. "Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28. Read more about Phase II cancer clinical trials with heterogeneous patient populations.PubMed
Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test. Kwak, Minjung, and Sin-Ho Jung. "Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16. Read more about Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.PubMed
Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint. Jung, Sin-Ho. "Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint." Med Res Arch 5, no. 7 (2017). Read more about Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint.PubMed
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy. Musolino, Antonino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H. Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, Hervé Bonnefoi et al. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18. Read more about Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy.PubMed
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Anderson, Gray R., Suzanne E. Wardell, Merve Cakir, Lorin Crawford, Jim C. Leeds, Daniel P. Nussbaum, Pallavi S. Shankar, Ryan S. Soderquist, Elizabeth M. Stein, Jennifer P. Tingley et al. "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175. Read more about PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.PubMed
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. Stinchcombe, Thomas E., Ying Zhang, Everett E. Vokes, Joan H. Schiller, Jeffrey D. Bradley, Karen Kelly, Walter J. Curran, Steven E. Schild, Benjamin Movsas, Gerald Clamon et al. "Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol 35, no. 25 (2017): 2885-2892. Read more about Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.PubMed
Power and sample size calculation for microarray studies (Fortran). Jung, Sin-Ho, and Stanley S Young. Power and sample size calculation for microarray studies (Fortran).., 2012. Read more about Power and sample size calculation for microarray studies (Fortran).
Practical designs for Phase I combination studies in oncology. Wages, Nolan A., Anastasia Ivanova, and Olga Marchenko. "Practical designs for Phase I combination studies in oncology." J Biopharm Stat 26, no. 1 (2016): 150-66. Read more about Practical designs for Phase I combination studies in oncology.PubMed
Prediction of a time-to-event trait using genome wide SNP data. Kim, Jinseog, Insuk Sohn, Dae-Soon Son, Dong Hwan Kim, Taejin Ahn, and Sin-Ho Jung. "Prediction of a time-to-event trait using genome wide SNP data." BMC Bioinformatics 14 (2013): 58. Read more about Prediction of a time-to-event trait using genome wide SNP data.PubMed
Predictive accuracy of covariates for event times. Chen, Li, D Y. Lin, and Donglin Zeng. "Predictive accuracy of covariates for event times." Biometrika 99, no. 3 (2012): 615-630. Read more about Predictive accuracy of covariates for event times.PubMed
Principal Components Adjusted Variable Screening. Liu, Zhongkai, Rui Song, Donglin Zeng, and Jiajia Zhang. "Principal Components Adjusted Variable Screening." Comput Stat Data Anal 110 (2017): 134-144. Read more about Principal Components Adjusted Variable Screening.PubMed
Properties of Estimators in Exponential Family Settings with Observation-based Stopping Rules. Milanzi, Elasma, Geert Molenberghs, Ariel Alonso, Michael G. Kenward, Geert Verbeke, Anastasios A. Tsiatis, and Marie Davidian. "Properties of Estimators in Exponential Family Settings with Observation-based Stopping Rules." J Biom Biostat 7, no. 1 (2016). Read more about Properties of Estimators in Exponential Family Settings with Observation-based Stopping Rules.PubMed
Proportional hazards model with a change point for clustered event data. Deng, Yu, Donglin Zeng, Jinying Zhao, and Jianwen Cai. "Proportional hazards model with a change point for clustered event data." Biometrics 73, no. 3 (2017): 835-845. Read more about Proportional hazards model with a change point for clustered event data.PubMed
Proportional rate models for recurrent time event data under dependent censoring: A comparative study. Amorim, Leila D. A. F., Jianwen Cai, and Donglin Zeng. "Proportional rate models for recurrent time event data under dependent censoring: A comparative study." In Recent Advances in Biostatistics, 123-141. Vol. 4., 2011. Read more about Proportional rate models for recurrent time event data under dependent censoring: A comparative study.
Quantifying the average of the time-varying hazard ratio via a class of transformations. Chen, Qingxia, Donglin Zeng, Joseph G. Ibrahim, Ming-Hui Chen, Zhiying Pan, and Xiaodong Xue. "Quantifying the average of the time-varying hazard ratio via a class of transformations." Lifetime Data Anal 21, no. 2 (2015): 259-79. Read more about Quantifying the average of the time-varying hazard ratio via a class of transformations.PubMed
Quantile Regression Models for Current Status Data. Ou, Fang-Shu, Donglin Zeng, and Jianwen Cai. "Quantile Regression Models for Current Status Data." J Stat Plan Inference 178 (2016): 112-127. Read more about Quantile Regression Models for Current Status Data.PubMed
Randomized phase II cancer clinical tirals Jung, Sin-Ho. Randomized phase II cancer clinical tirals. Boca Raton: Chapman & Hall/CRC Press, 2013. Read more about Randomized phase II cancer clinical tirals
Randomized phase II clinical trials. Jung, Sin-Ho, and Daniel J. Sargent. "Randomized phase II clinical trials." J Biopharm Stat 24, no. 4 (2014): 802-16. Read more about Randomized phase II clinical trials.PubMed
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Harbeck, Nadia, Oleg Lipatov, Mona Frolova, Dmitry Udovitsa, Eldar Topuzov, Doina Elena Ganea-Motan, Roumen Nakov, Pritibha Singh, Anita Rudy, and Kimberly Blackwell. "Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67. Read more about Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.PubMed
Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups. Xue, Xiaoqiang, Matthew C. Foster, and Anastasia Ivanova. "Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups." J Biopharm Stat 29, no. 4 (2019): 625-634. Read more about Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups.PubMed
Recent progresses in outcome-dependent sampling with failure time data. Ding, Jieli, Tsui-Shan Lu, Jianwen Cai, and Haibo Zhou. "Recent progresses in outcome-dependent sampling with failure time data." Lifetime Data Anal 23, no. 1 (2017): 57-82. Read more about Recent progresses in outcome-dependent sampling with failure time data.PubMed
Regression analysis for secondary response variable in a case-cohort study. Pan, Yinghao, Jianwen Cai, Sangmi Kim, and Haibo Zhou. "Regression analysis for secondary response variable in a case-cohort study." Biometrics 74, no. 3 (2018): 1014-1022. Read more about Regression analysis for secondary response variable in a case-cohort study.PubMed
Regression analysis of sparse asynchronous longitudinal data. Cao, Hongyuan, Donglin Zeng, and Jason P. Fine. "Regression analysis of sparse asynchronous longitudinal data." J R Stat Soc Series B Stat Methodol 77, no. 4 (2015): 755-776. Read more about Regression analysis of sparse asynchronous longitudinal data.PubMed
Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. Yao, Xiaoxin I., Xiaofei Wang, Paul J. Speicher, Shelley E Hwang, Perry Cheng, David H. Harpole, Mark F. Berry, Deborah Schrag, and Herbert H. Pang. "Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies." J Natl Cancer Inst 109, no. 8 (2017). Read more about Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies.PubMed
Research methods for clinical trials in personalized medicine: A systematic review. Ren, Zheng, Marie Davidian, Stephen L. George, Richard M. Goldberg, Fred A. Wright, Anastasios A. Tsiatis, and Michael R. Kosorok. "Research methods for clinical trials in personalized medicine: A systematic review." In Lost In Translation: Barriers to Incentives for Translational Research in Medical Sciences. Singapore: World Scientific, 2014. Read more about Research methods for clinical trials in personalized medicine: A systematic review.
Reweighted estimators for additive hazard model with censoring indicators missing at random. Chen, Xiaolin, and Jianwen Cai. "Reweighted estimators for additive hazard model with censoring indicators missing at random." Lifetime Data Anal 24, no. 2 (2018): 224-249. Read more about Reweighted estimators for additive hazard model with censoring indicators missing at random.PubMed
Risk calculators are useful but... Wang, Xiaofei, and Mark F. Berry. "Risk calculators are useful but..." J Thorac Cardiovasc Surg 151, no. 3 (2016): 706-707. Read more about Risk calculators are useful but...PubMed
ROC curve estimation under test-result-dependent sampling. Wang, Xiaofei, Junling Ma, and Stephen L. George. "ROC curve estimation under test-result-dependent sampling." Biostatistics 14, no. 1 (2013): 160-72. Read more about ROC curve estimation under test-result-dependent sampling.PubMed
Sample size and power determination in joint modeling of longitudinal and survival data. Chen, Liddy M., Joseph G. Ibrahim, and Haitao Chu. "Sample size and power determination in joint modeling of longitudinal and survival data." Stat Med 30, no. 18 (2011): 2295-309. Read more about Sample size and power determination in joint modeling of longitudinal and survival data.PubMed
Sample size calculation for comparing survival curves under general hypotheses testing (Fortran). Jung, Sin-Ho, and Shein-Chung Chow. Sample size calculation for comparing survival curves under general hypotheses testing (Fortran).., 2012. Read more about Sample size calculation for comparing survival curves under general hypotheses testing (Fortran).
Sample size calculation for studies with grouped survival data. Li, Zhiguo, Xiaofei Wang, Yuan Wu, and Kouros Owzar. "Sample size calculation for studies with grouped survival data." Stat Med 37, no. 27 (2018): 3904-3917. Read more about Sample size calculation for studies with grouped survival data.PubMed
Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes. Pang, Herbert, and Sin-Ho Jung. "Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes." Genet Epidemiol 37, no. 3 (2013): 276-82. Read more about Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes.PubMed
Sample size determination in shared frailty models for multivariate time-to-event data. Chen, Liddy M., Joseph G. Ibrahim, and Haitao Chu. "Sample size determination in shared frailty models for multivariate time-to-event data." J Biopharm Stat 24, no. 4 (2014): 908-23. Read more about Sample size determination in shared frailty models for multivariate time-to-event data.PubMed
Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm. Esserman, Denise, Yingqi Zhao, Yiyun Tang, and Jianwen Cai. "Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm." Stat Med 32, no. 12 (2013): 2140-54. Read more about Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm.PubMed
Sample size/power calculation for stratified case-cohort design. Hu, Wenrong, Jianwen Cai, and Donglin Zeng. "Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85. Read more about Sample size/power calculation for stratified case-cohort design.PubMed
SAS Macro BSMED: Bayesian survival meta-experimental design using historical data. Ibrahim, Joseph G., Yeongjin Gwon, and Ming-Hui Chen. "SAS Macro BSMED: Bayesian survival meta-experimental design using historical data." In Pharmaceutical Statistics Using SAS. Cary: SAS Institute Inc, 2016. Read more about SAS Macro BSMED: Bayesian survival meta-experimental design using historical data.
Seamless Phase IIa/IIb and enhanced dose-finding adaptive design. Yuan, Jiacheng, Herbert Pang, Tiejun Tong, Dong Xi, Wenzhao Guo, and Peter Mesenbrink. "Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23. Read more about Seamless Phase IIa/IIb and enhanced dose-finding adaptive design.PubMed
Secondary outcome analysis for data from an outcome-dependent sampling design. Pan, Yinghao, Jianwen Cai, Matthew P. Longnecker, and Haibo Zhou. "Secondary outcome analysis for data from an outcome-dependent sampling design." Stat Med 37, no. 15 (2018): 2321-2337. Read more about Secondary outcome analysis for data from an outcome-dependent sampling design.PubMed
Selection of the initial design for the two-stage continual reassessment method. Jia, Xiaoyu, Anastasia Ivanova, and Shing M. Lee. "Selection of the initial design for the two-stage continual reassessment method." J Biopharm Stat 27, no. 3 (2017): 495-506. Read more about Selection of the initial design for the two-stage continual reassessment method.PubMed
Semiparametric additive marginal regression models for multiple type recurrent events. Chen, Xiaolin, Qihua Wang, Jianwen Cai, and Viswanathan Shankar. "Semiparametric additive marginal regression models for multiple type recurrent events." Lifetime Data Anal 18, no. 4 (2012): 504-27. Read more about Semiparametric additive marginal regression models for multiple type recurrent events.PubMed
Semiparametric Additive Model for Estimating Risk Difference in Multicenter Studies. Zeng, Donglin, Noorie Hyun, and Jianwen Cai. "Semiparametric Additive Model for Estimating Risk Difference in Multicenter Studies." Biostat Epidemiol 2, no. 1 (2018): 84-98. Read more about Semiparametric Additive Model for Estimating Risk Difference in Multicenter Studies.PubMed
Semiparametric Bayes local additive models for longitudinal data. Hua, Zhaowei, Hongtu Zhu, and David B. Dunson. "Semiparametric Bayes local additive models for longitudinal data." Stat Biosci 7, no. 1 (2015): 90-107. Read more about Semiparametric Bayes local additive models for longitudinal data.PubMed
Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome. Zhou, Haibo, Yuanshan Wu, Yanyan Liu, and Jianwen Cai. "Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome." Biostatistics 12, no. 3 (2011): 521-34. Read more about Semiparametric inference for a 2-stage outcome-auxiliary-dependent sampling design with continuous outcome.PubMed
Semiparametric inference for a two-stage outcome-dependent sampling design with interval-censored failure time data. Zhou, Qingning, Jianwen Cai, and Haibo Zhou. "Semiparametric inference for a two-stage outcome-dependent sampling design with interval-censored failure time data." Lifetime Data Anal 26, no. 1 (2020): 85-108. Read more about Semiparametric inference for a two-stage outcome-dependent sampling design with interval-censored failure time data.PubMed
Semiparametric Inference for Data with a Continuous Outcome from a Two-Phase Probability Dependent Sampling Scheme. Zhou, Haibo, Wangli Xu, Donglin Zeng, and Jianwen Cai. "Semiparametric Inference for Data with a Continuous Outcome from a Two-Phase Probability Dependent Sampling Scheme." J R Stat Soc Series B Stat Methodol 76, no. 1 (2014): 197-215. Read more about Semiparametric Inference for Data with a Continuous Outcome from a Two-Phase Probability Dependent Sampling Scheme.PubMed
Semiparametric inference on the penetrances of rare genetic mutations based on a case-family design. Zhang, Hong, Donglin Zeng, Sylviane Olschwang, and Kai Yu. "Semiparametric inference on the penetrances of rare genetic mutations based on a case-family design." J Stat Plan Inference 143, no. 2 (2013): 368-377. Read more about Semiparametric inference on the penetrances of rare genetic mutations based on a case-family design.PubMed
SEMIPARAMETRIC REGRESSION ANALYSIS OF REPEATED CURRENT STATUS DATA. Liang, Baosheng, Xingwei Tong, Donglin Zeng, and Yuanjia Wang. "SEMIPARAMETRIC REGRESSION ANALYSIS OF REPEATED CURRENT STATUS DATA." Stat Sin 27, no. 3 (2017): 1079-1100. Read more about SEMIPARAMETRIC REGRESSION ANALYSIS OF REPEATED CURRENT STATUS DATA.PubMed
SEMIPARAMETRIC ROC ANALYSIS USING ACCELERATED REGRESSION MODELS. Kim, Eunhee, and Donglin Zeng. "SEMIPARAMETRIC ROC ANALYSIS USING ACCELERATED REGRESSION MODELS." Stat Sin 23 (2013): 829-851. Read more about SEMIPARAMETRIC ROC ANALYSIS USING ACCELERATED REGRESSION MODELS.PubMed
Semiparametric sieve maximum likelihood estimation under cure model with partly interval censored and left truncated data for application to spontaneous abortion. Wu, Yuan, Christina D. Chambers, and Ronghui Xu. "Semiparametric sieve maximum likelihood estimation under cure model with partly interval censored and left truncated data for application to spontaneous abortion." Lifetime Data Anal 25, no. 3 (2019): 507-528. Read more about Semiparametric sieve maximum likelihood estimation under cure model with partly interval censored and left truncated data for application to spontaneous abortion.PubMed
Semiparametric Transformation Rate Model for Recurrent Event Data. Zeng, Donglin, Douglas E. Schaubel, and Jianwen Cai. "Semiparametric Transformation Rate Model for Recurrent Event Data." Stat Biosci 3, no. 2 (2011): 187-207. Read more about Semiparametric Transformation Rate Model for Recurrent Event Data.PubMed
Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment. Zhao, Yue, Benjamin R. Saville, Haibo Zhou, and Gary G. Koch. "Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment." J Biopharm Stat 26, no. 2 (2016): 269-79. Read more about Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment.PubMed
Sequential multiple assignment randomization trials with enrichment design. Liu, Ying, Yuanjia Wang, and Donglin Zeng. "Sequential multiple assignment randomization trials with enrichment design." Biometrics 73, no. 2 (2017): 378-390. Read more about Sequential multiple assignment randomization trials with enrichment design.PubMed
SGPP: spatial Gaussian predictive process models for neuroimaging data. Hyun, Jung Won, Yimei Li, John H. Gilmore, Zhaohua Lu, Martin Styner, and Hongtu Zhu. "SGPP: spatial Gaussian predictive process models for neuroimaging data." Neuroimage 89 (2014): 70-80. Read more about SGPP: spatial Gaussian predictive process models for neuroimaging data.PubMed
Simon’s like design with relaxed futility stopping (Web) Ivanova, Anastasia, and A Deal. Simon’s like design with relaxed futility stopping (Web)., 2017. Read more about Simon’s like design with relaxed futility stopping (Web)
Sparse and Efficient Estimation for Partial Spline Models with Increasing Dimension. Cheng, Guang, Hao Helen Zhang, and Zuofeng Shang. "Sparse and Efficient Estimation for Partial Spline Models with Increasing Dimension." Ann Inst Stat Math 67, no. 1 (2015): 93-127. Read more about Sparse and Efficient Estimation for Partial Spline Models with Increasing Dimension.PubMed
Statistical aspect of translational and correlative studies in clinical trials. Pang, Herbert, and Xiaofei Wang. "Statistical aspect of translational and correlative studies in clinical trials." Chin Clin Oncol 5, no. 1 (2016): 11. Read more about Statistical aspect of translational and correlative studies in clinical trials.PubMed
Statistical inference for the additive hazards model under outcome-dependent sampling. Yu, Jichang, Yanyan Liu, Dale P. Sandler, and Haibo Zhou. "Statistical inference for the additive hazards model under outcome-dependent sampling." Can J Stat 43, no. 3 (2015): 436-453. Read more about Statistical inference for the additive hazards model under outcome-dependent sampling.PubMed
Statistical inferences for data from studies conducted with an aggregated multivariate outcome-dependent sample design. Lu, Tsui-Shan, Matthew P. Longnecker, and Haibo Zhou. "Statistical inferences for data from studies conducted with an aggregated multivariate outcome-dependent sample design." Stat Med 36, no. 6 (2017): 985-997. Read more about Statistical inferences for data from studies conducted with an aggregated multivariate outcome-dependent sample design.PubMed
Statistical issues and advances in cancer precision medicine research. Nasution, Marlina D., and Xiaofei Wang. "Statistical issues and advances in cancer precision medicine research." J Biopharm Stat 28, no. 2 (2018): 215-216. Read more about Statistical issues and advances in cancer precision medicine research.PubMed
Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials. Jung, Sin-Ho. "Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials." Contemp Clin Trials 42 (2015): 9-17. Read more about Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.PubMed
Statistical Issues in the Design and Analysis of nCounter Projects. Jung, Sin-Ho, and Insuk Sohn. "Statistical Issues in the Design and Analysis of nCounter Projects." Cancer Inform 13, no. Suppl 7 (2014): 35-43. Read more about Statistical Issues in the Design and Analysis of nCounter Projects.PubMed
Statistical Methods for Conditional Survival Analysis. Jung, Sin-Ho, Ho Yun Lee, and Shein-Chung Chow. "Statistical Methods for Conditional Survival Analysis." J Biopharm Stat 28, no. 5 (2018): 927-938. Read more about Statistical Methods for Conditional Survival Analysis.PubMed
Stratified Fisher's exact test and its sample size calculation. Jung, Sin-Ho. "Stratified Fisher's exact test and its sample size calculation." Biom J 56, no. 1 (2014): 129-40. Read more about Stratified Fisher's exact test and its sample size calculation.PubMed
Subgroup detection and sample size calculation with proportional hazards regression for survival data. Kang, Suhyun, Wenbin Lu, and Rui Song. "Subgroup detection and sample size calculation with proportional hazards regression for survival data." Stat Med 36, no. 29 (2017): 4646-4659. Read more about Subgroup detection and sample size calculation with proportional hazards regression for survival data.PubMed
SurvLong: Analysis of proportional hazards model with sparse longitudinal covariates (R). Cao, Hongyuan, Mathew M. Churpek, Donglin Zeng, Jason P. Fine, and Shannon T. Holloway. SurvLong: Analysis of proportional hazards model with sparse longitudinal covariates (R).. 1.0 ed., 2015. Read more about SurvLong: Analysis of proportional hazards model with sparse longitudinal covariates (R).
survSNP: Power and sample size calculations for SNP association studies with censored time-to-event outcomes (R). Jung, Sin-Ho, and Stanley S Young. survSNP: Power and sample size calculations for SNP association studies with censored time-to-event outcomes (R).., 2012. Read more about survSNP: Power and sample size calculations for SNP association studies with censored time-to-event outcomes (R).
Targeted cancer clinical trials George, Stephen L., and Xiaofei Wang. "Targeted cancer clinical trials." In Designs for Clinical Trials, 157-177. New York: Springer, 2012. Read more about Targeted cancer clinical trials
Tests of trend between disease outcomes and ordinal covariates discretized from underlying continuous variables: simulation studies and applications to NHANES 2007-2008. Brownstein, Naomi C., and Jianwen Cai. "Tests of trend between disease outcomes and ordinal covariates discretized from underlying continuous variables: simulation studies and applications to NHANES 2007-2008." BMC Med Res Methodol 19, no. 1 (2019): 2. Read more about Tests of trend between disease outcomes and ordinal covariates discretized from underlying continuous variables: simulation studies and applications to NHANES 2007-2008.PubMed
The rapid enrollment design for Phase I clinical trials. Ivanova, Anastasia, Yunfei Wang, and Matthew C. Foster. "The rapid enrollment design for Phase I clinical trials." Stat Med 35, no. 15 (2016): 2516-24. Read more about The rapid enrollment design for Phase I clinical trials.PubMed
The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. Barry, William T., Charles M. Perou, Kelly P Marcom, Lisa A. Carey, and Joseph G. Ibrahim. "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88. Read more about The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.PubMed
Time-dependent classification accuracy curve under marker-dependent sampling. Zhu, Zhaoyin, Xiaofei Wang, Paramita Saha-Chaudhuri, Andrzej S. Kosinski, and Stephen L. George. "Time-dependent classification accuracy curve under marker-dependent sampling." Biom J 58, no. 4 (2016): 974-92. Read more about Time-dependent classification accuracy curve under marker-dependent sampling.PubMed
Time-varying latent effect model for longitudinal data with informative observation times. Cai, Na, Wenbin Lu, and Hao Helen Zhang. "Time-varying latent effect model for longitudinal data with informative observation times." Biometrics 68, no. 4 (2012): 1093-102. Read more about Time-varying latent effect model for longitudinal data with informative observation times.PubMed
Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Schild, Steven E., Wen Fan, Thomas E. Stinchcombe, Everett E. Vokes, Suresh S. Ramalingam, Jeffrey D. Bradley, Karen Kelly, Herbert H. Pang, and Xiaofei Wang. "Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer." J Thorac Oncol 14, no. 2 (2019): 298-303. Read more about Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.PubMed
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Freedman, Rachel A., Rebecca S. Gelman, Jeffrey S. Wefel, Michelle E. Melisko, Kenneth R. Hess, Roisin M. Connolly, Catherine H. Van Poznak, Polly A. Niravath, Shannon L. Puhalla, Nuhad Ibrahim et al. "Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52. Read more about Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.PubMed
Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. Caron, Whitney P., John C. Lay, Alan M. Fong, Ninh M. La-Beck, Parag Kumar, Suzanne E. Newman, Haibo Zhou, Jane H. Monaco, Daniel L. Clarke-Pearson, Wendy R. Brewster et al. "Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606. Read more about Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.PubMed
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742. Read more about Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.PubMed
Tuning Parameter Selection in Cox Proportional Hazards Model with a Diverging Number of Parameters. Ni, Ai, and Jianwen Cai. "Tuning Parameter Selection in Cox Proportional Hazards Model with a Diverging Number of Parameters." Scand Stat Theory Appl 45, no. 3 (2018): 557-570. Read more about Tuning Parameter Selection in Cox Proportional Hazards Model with a Diverging Number of Parameters.PubMed
Two-stage design for phase II oncology trials with relaxed futility stopping. Ivanova, Anastasia, and Allison M. Deal. "Two-stage design for phase II oncology trials with relaxed futility stopping." Stat Interface 9, no. 1 (2016): 93-98. Read more about Two-stage design for phase II oncology trials with relaxed futility stopping.PubMed
Type I error control for tree classification. Jung, Sin-Ho, Yong Chen, and Hongshik Ahn. "Type I error control for tree classification." Cancer Inform 13, no. Suppl 7 (2014): 11-8. Read more about Type I error control for tree classification.PubMed
Using Structural Equation Modeling to Assess the Links between Tobacco Smoke Exposure, Volatile Organic Compounds, and Respiratory Function for Adolescents Aged 6 to 18 in the United States. Shook-Sa, Bonnie E., Ding-Geng Chen, and Haibo Zhou. "Using Structural Equation Modeling to Assess the Links between Tobacco Smoke Exposure, Volatile Organic Compounds, and Respiratory Function for Adolescents Aged 6 to 18 in the United States." Int J Environ Res Public Health 14, no. 10 (2017). Read more about Using Structural Equation Modeling to Assess the Links between Tobacco Smoke Exposure, Volatile Organic Compounds, and Respiratory Function for Adolescents Aged 6 to 18 in the United States.PubMed
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Wang, Xiaofei, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, Thomas E. Stinchcombe, Jeffrey Crawford, Robert Kratzke et al. "Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198. Read more about Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.PubMed
Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Wang, Xiaofei, Lin Gu, Ying Zhang, Daniel J. Sargent, William Richards, Apar Kishor Ganti, Jeffery Crawford, Harvey Jay Cohen, Thomas Stinchcombe, Everett Vokes et al. "Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups." Lung Cancer 90, no. 2 (2015): 281-7. Read more about Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.PubMed
Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials. Yuan, Shuai, Hao Helen Zhang, and Marie Davidian. "Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials." Stat Med 31, no. 29 (2012): 3789-804. Read more about Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials.PubMed
Variable selection for optimal treatment decision. Lu, Wenbin, Hao Helen Zhang, and Donglin Zeng. "Variable selection for optimal treatment decision." Stat Methods Med Res 22, no. 5 (2013): 493-504. Read more about Variable selection for optimal treatment decision.PubMed